Logo image of GOVX

GEOVAX LABS INC (GOVX) Stock Fundamental Analysis

NASDAQ:GOVX - Nasdaq - US3736786068 - Common Stock - Currency: USD

0.8295  -0.07 (-8.08%)

After market: 0.86 +0.03 (+3.68%)

Fundamental Rating

3

GOVX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 568 industry peers in the Biotechnology industry. While GOVX seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, GOVX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

GOVX had negative earnings in the past year.
In the past year GOVX has reported a negative cash flow from operations.
GOVX had negative earnings in each of the past 5 years.
In the past 5 years GOVX always reported negative operating cash flow.
GOVX Yearly Net Income VS EBIT VS OCF VS FCFGOVX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

The Return On Assets of GOVX (-306.43%) is worse than 94.54% of its industry peers.
With a Return On Equity value of -495.04%, GOVX is not doing good in the industry: 79.23% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -306.43%
ROE -495.04%
ROIC N/A
ROA(3y)-210.29%
ROA(5y)-163.35%
ROE(3y)-332.78%
ROE(5y)-290.99%
ROIC(3y)N/A
ROIC(5y)N/A
GOVX Yearly ROA, ROE, ROICGOVX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 -1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for GOVX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GOVX Yearly Profit, Operating, Gross MarginsGOVX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K

More info and screens

5

2. Health

2.1 Basic Checks

GOVX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, GOVX has more shares outstanding
The number of shares outstanding for GOVX has been increased compared to 5 years ago.
There is no outstanding debt for GOVX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
GOVX Yearly Shares OutstandingGOVX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
GOVX Yearly Total Debt VS Total AssetsGOVX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

Based on the Altman-Z score of -28.97, we must say that GOVX is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of GOVX (-28.97) is worse than 89.61% of its industry peers.
There is no outstanding debt for GOVX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -28.97
ROIC/WACCN/A
WACC10.33%
GOVX Yearly LT Debt VS Equity VS FCFGOVX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M

2.3 Liquidity

GOVX has a Current Ratio of 2.55. This indicates that GOVX is financially healthy and has no problem in meeting its short term obligations.
GOVX's Current ratio of 2.55 is on the low side compared to the rest of the industry. GOVX is outperformed by 70.07% of its industry peers.
GOVX has a Quick Ratio of 2.55. This indicates that GOVX is financially healthy and has no problem in meeting its short term obligations.
GOVX's Quick ratio of 2.55 is on the low side compared to the rest of the industry. GOVX is outperformed by 68.66% of its industry peers.
Industry RankSector Rank
Current Ratio 2.55
Quick Ratio 2.55
GOVX Yearly Current Assets VS Current LiabilitesGOVX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 76.33% over the past year.
The Revenue has been growing by 27.45% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)76.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.79%
Revenue 1Y (TTM)N/A
Revenue growth 3Y117.28%
Revenue growth 5Y27.45%
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, GOVX will show a very strong growth in Earnings Per Share. The EPS will grow by 34.44% on average per year.
Based on estimates for the next years, GOVX will show a very strong growth in Revenue. The Revenue will grow by 281.10% on average per year.
EPS Next Y77.48%
EPS Next 2Y34.44%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year40.18%
Revenue Next 2Y6.86%
Revenue Next 3Y281.1%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
GOVX Yearly Revenue VS EstimatesGOVX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2024 2025 2026 2027 100M 200M 300M
GOVX Yearly EPS VS EstimatesGOVX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 -5 -10 -15 -20

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GOVX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GOVX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GOVX Price Earnings VS Forward Price EarningsGOVX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GOVX Per share dataGOVX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4

4.3 Compensation for Growth

A more expensive valuation may be justified as GOVX's earnings are expected to grow with 34.44% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.44%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for GOVX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GEOVAX LABS INC

NASDAQ:GOVX (4/17/2025, 8:25:19 PM)

After market: 0.86 +0.03 (+3.68%)

0.8295

-0.07 (-8.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-27 2025-03-27/amc
Earnings (Next)05-12 2025-05-12
Inst Owners3.07%
Inst Owner Change0%
Ins Owners0.81%
Ins Owner Change7.89%
Market Cap11.48M
Analysts81.82
Price Target14.89 (1695.06%)
Short Float %7.42%
Short Ratio1.02
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)50.66%
Min EPS beat(2)39.62%
Max EPS beat(2)61.7%
EPS beat(4)4
Avg EPS beat(4)49.95%
Min EPS beat(4)39.62%
Max EPS beat(4)61.7%
EPS beat(8)5
Avg EPS beat(8)-26.77%
EPS beat(12)7
Avg EPS beat(12)-17.81%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)66.61%
Min Revenue beat(2)-64.4%
Max Revenue beat(2)197.61%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-31.43%
EPS NQ rev (3m)-39.39%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)-35.56%
Revenue NQ rev (3m)-33.33%
Revenue NY rev (1m)-44.04%
Revenue NY rev (3m)-44.04%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.9
P/FCF N/A
P/OCF N/A
P/B 2.27
P/tB 2.27
EV/EBITDA N/A
EPS(TTM)-5.67
EYN/A
EPS(NY)-1.28
Fwd EYN/A
FCF(TTM)-1.78
FCFYN/A
OCF(TTM)-1.78
OCFYN/A
SpS0.29
BVpS0.36
TBVpS0.36
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -306.43%
ROE -495.04%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-210.29%
ROA(5y)-163.35%
ROE(3y)-332.78%
ROE(5y)-290.99%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.48
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 21.7%
Cap/Sales 0.52%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.55
Quick Ratio 2.55
Altman-Z -28.97
F-Score5
WACC10.33%
ROIC/WACCN/A
Cap/Depr(3y)108.76%
Cap/Depr(5y)249.22%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)76.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.79%
EPS Next Y77.48%
EPS Next 2Y34.44%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3Y117.28%
Revenue growth 5Y27.45%
Sales Q2Q%N/A
Revenue Next Year40.18%
Revenue Next 2Y6.86%
Revenue Next 3Y281.1%
Revenue Next 5YN/A
EBIT growth 1Y5.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-83000.3%
EBIT Next 3Y649.13%
EBIT Next 5YN/A
FCF growth 1Y2.09%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1.98%
OCF growth 3YN/A
OCF growth 5YN/A